Literature DB >> 10457122

Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports.

H R Smith1, A M Croft, M M Black.   

Abstract

Mefloquine is a relatively new antimalarial drug which has been associated with a wide variety of adverse effects, including skin reactions. In order to evaluate the range and frequency of mefloquine's dermatological effects, we searched the scientific literature for published case reports of such effects. We found 74 case reports, published between the years 1983 and 1997. Pruritus and maculopapular rash are the dermatological effects most commonly associated with mefloquine: their approximate frequency is 4-10% for pruritus, and up to 30% for nonspecific maculopapular rash. Adverse effects associated less commonly with mefloquine include urticaria, facial lesions and cutaneous vasculitis. One case of Stevens-Johnson syndrome and one fatal case of toxic epidermal necrolysis occurred. Appropriate primary studies of mefloquine use should be carried out to elucidate the epidemiology and aetiology of dermatological and other adverse effects of the drug.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10457122     DOI: 10.1046/j.1365-2230.1999.00471.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  8 in total

Review 1.  A lesson learnt: the rise and fall of Lariam and Halfan.

Authors:  Ashley M Croft
Journal:  J R Soc Med       Date:  2007-04       Impact factor: 5.344

Review 2.  Malaria: prevention in travellers.

Authors:  Ashley M Croft
Journal:  BMJ Clin Evid       Date:  2007-11-29

Review 3.  Extracts from "Clinical Evidence". Malaria: prevention in travellers.

Authors:  A Croft
Journal:  BMJ       Date:  2000-07-15

Review 4.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 5.  WITHDRAWN: Mefloquine for preventing malaria in non-immune adult travellers.

Authors:  A M J Croft; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

6.  Adverse effects of the antimalaria drug, mefloquine: due to primary liver damage with secondary thyroid involvement?

Authors:  Ashley M Croft; Andrew Herxheimer
Journal:  BMC Public Health       Date:  2002-03-25       Impact factor: 3.295

7.  Mefloquine, an anti-malaria agent, causes reactive oxygen species-dependent cell death in mast cells via a secretory granule-mediated pathway.

Authors:  Aida Paivandy; Gabriela Calounova; Behdad Zarnegar; Helena Ohrvik; Fabio R Melo; Gunnar Pejler
Journal:  Pharmacol Res Perspect       Date:  2014-08-24

8.  In vitro hepatic metabolism of mefloquine using microsomes from cats, dogs and the common brush-tailed possum (Trichosurus vulpecula).

Authors:  Aaron Michael Izes; Benjamin Kimble; Jacqueline Marie Norris; Merran Govendir
Journal:  PLoS One       Date:  2020-04-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.